[18] Clearly, the higher
tumor burden at baseline in stage IV patients adversely affected responses.
Positron emission tomography (PET) imaging of metabolic
tumor burden at diagnosis and after induction therapy can help identify patients most at risk of follicular lymphoma (FL) recurrence, but more work is needed to differentiate high - risk and moderate - risk patients, suggested findings from a pooled analysis of data from three prospective clinical trials, published in Blood.
Pooled data show PET imaging of metabolic
tumor burden at diagnosis helps identify patients most at risk of FL recurrence.
Not exact matches
The authors conclude, «Unvalidated guidelines to prevent neuroimaging in patients with headaches may reduce the perceived global economic
burden at the expense of medical errors, delayed diagnoses, and inferior outcomes for patients with brain
tumor.»
Average
tumor burden and standard deviations were derived from
at least four animals per group.
The researchers therefore looked
at possible indicators of
tumor burden, including direct measurements such as lactate dehydrogenase and the number or volume of metastases, or indirect evidence such as leaving the primary
tumor in place or if the goal of treatment was palliation.